# NEJM article on Retinopathy Screening interval in Type 1s
**URL:** https://forum.fudiabetes.org/t/nejm-article-on-retinopathy-screening-interval-in-type-1s/1517
**Category:** Type 1 & LADA
**Tags:** eyecare
**Created:** [August 2, 2017, 6:01pm UTC](https://forum.fudiabetes.org/t/nejm-article-on-retinopathy-screening-interval-in-type-1s/1517 "2017-08-02T18:01:06Z")
**Posts on this page:** 10
**Page:** 1
### Author:  [@Chris](https://forum.fudiabetes.org/u/Chris)
#### Post date: [August 2, 2017, 6:01pm UTC](https://forum.fudiabetes.org/t/nejm-article-on-retinopathy-screening-interval-in-type-1s/1517/1 "2017-08-02T18:01:07Z")
> **[Frequency of Evidence-Based Screening for Retinopathy in Type 1 Diabetes | NEJM](https://www.nejm.org/doi/full/10.1056/NEJMoa1612836)**
>
> Original Article from The New England Journal of Medicine — Frequency of Evidence-Based Screening for Retinopathy in Type 1 Diabetes
Interesting article, showing that for Type 1’s with no evidence of retinopathy, extending your eye screenings may be a reasonable solution.
Also interesting, they defined control as having an A1C in the 6% range, and out of control in the 10% range.
---
### Author:  [@TiaG](https://forum.fudiabetes.org/u/TiaG)
#### Post date: [August 2, 2017, 6:22pm UTC](https://forum.fudiabetes.org/t/nejm-article-on-retinopathy-screening-interval-in-type-1s/1517/2 "2017-08-02T18:22:31Z")
there’s a huge gap between 6% and 10%!
---
### Author:  [@Chris](https://forum.fudiabetes.org/u/Chris)
#### Post date: [August 2, 2017, 6:35pm UTC](https://forum.fudiabetes.org/t/nejm-article-on-retinopathy-screening-interval-in-type-1s/1517/3 "2017-08-02T18:35:51Z")
That is very true, but I found it interesting that they chose a more modern definition of tight control, as opposed to a the more standard 7 or below.
---
### Author:  [@TiaG](https://forum.fudiabetes.org/u/TiaG)
#### Post date: [August 2, 2017, 6:39pm UTC](https://forum.fudiabetes.org/t/nejm-article-on-retinopathy-screening-interval-in-type-1s/1517/4 "2017-08-02T18:39:56Z")
well i’m guessing they’re looking at the risk rates. Retinopathy is incredibly prevalent for T1Ds; I would assume that most get it eventually, and that even “tight” control doesn’t prevent it if you define tight as 7% or below. You really need to get to the nondiabetic range before it’s an issue if you’re looking at 30-year prevalence rates.
---
### Author:  [@Chris](https://forum.fudiabetes.org/u/Chris)
#### Post date: [August 2, 2017, 6:41pm UTC](https://forum.fudiabetes.org/t/nejm-article-on-retinopathy-screening-interval-in-type-1s/1517/5 "2017-08-02T18:41:50Z")
I agree with you, all this article is saying to me, is that if you are in tight control, your clinically actionable retinopathy progression will be slow enough that you can feel ok in spacing out your dilated eye exams.
---
### Author:  [@docslotnick](https://forum.fudiabetes.org/u/docslotnick)
#### Post date: [August 2, 2017, 7:36pm UTC](https://forum.fudiabetes.org/t/nejm-article-on-retinopathy-screening-interval-in-type-1s/1517/6 "2017-08-02T19:36:55Z")
I’m in the 6% range, have no evidence of retinopathy or macular edema, and I’ll keep having my dilated retinal exams every six months, thank you.
---
### Author:  [@Sam](https://forum.fudiabetes.org/u/Sam)
#### Post date: [August 2, 2017, 9:10pm UTC](https://forum.fudiabetes.org/t/nejm-article-on-retinopathy-screening-interval-in-type-1s/1517/7 "2017-08-02T21:10:34Z")
Interesting bit in Dr. Najeeb’s insulin lecture number 4 about the microvascular risks such as retinopathy being elevated as a function of low c-peptide alone in t1d, even assuming perfect bg management
---
### Author:  [@TiaG](https://forum.fudiabetes.org/u/TiaG)
#### Post date: [August 2, 2017, 10:17pm UTC](https://forum.fudiabetes.org/t/nejm-article-on-retinopathy-screening-interval-in-type-1s/1517/8 "2017-08-02T22:17:21Z")
I do remember that. Saw this and wonder if there has been any progress since then:
[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3314360/](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3314360/)
---
### Author:  [@TiaG](https://forum.fudiabetes.org/u/TiaG)
#### Post date: [August 2, 2017, 10:26pm UTC](https://forum.fudiabetes.org/t/nejm-article-on-retinopathy-screening-interval-in-type-1s/1517/9 "2017-08-02T22:26:01Z")
Well, looks like one of the main companies testing the idea of using c-peptide as treatment folded its tent up after a phase 2b trial failed:
> **[Xconomy: Cebix Shuts Down Following Mid-Stage Trial of C-Peptide Drug](https://xconomy.com/san-diego/2015/02/23/cebix-shuts-down-following-mid-stage-trial-of-c-peptide-drug/)**
>
> San Diego-based Cebix, which raised about $50 million to advance a C-peptide replacement therapy for treating diabetes-related microvascular problems, has
---
### Author:  [@Chris](https://forum.fudiabetes.org/u/Chris)
#### Post date: [August 2, 2017, 11:06pm UTC](https://forum.fudiabetes.org/t/nejm-article-on-retinopathy-screening-interval-in-type-1s/1517/10 "2017-08-02T23:06:35Z")
Well, that is interesting. Really, they got off pretty inexpensively and quickly. They only had to raise $48 million dollars and got an answer showing their treatment, while a promising idea, was not helpful in patients.